Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ISIS 416858 (IONIS-FXIRX, an Antisense Inhibitor of Factor XI), Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis
NCT03358030 is registered in ClinicalTrials.gov with Ionis Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ISIS 416858 (IONIS-FXIRX, an Antisense Inhibitor of Factor XI), Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 26, 2017
- Completion date
- July 10, 2019
- Enrollment
- 213 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
end-stage renal disease (esrd)